HUTCHMED Advances HMPL-760 to Registrational Phase III for DLBCL in China
HCM sits 21% above its 52-week low of $11.505.
Summary
HUTCHMED has initiated a registrational Phase III clinical trial for its investigational drug HMPL-760 in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in China, a significant step towards potential market approval.
Key Events · Product Development and Regulatory · HCM
-
Phase III Trial Initiation
HUTCHMED has initiated a registrational Phase III clinical trial for HMPL-760 in combination with R-GemOx for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients in China, with the first patient dosed on March 20, 2026.
-
Targeting DLBCL
DLBCL is the most common aggressive non-Hodgkin lymphoma in China, with approximately 81,000 new cases estimated in 2022, representing a significant market opportunity for HMPL-760.
-
Encouraging Prior Results
The decision to advance to Phase III follows encouraging improvements in objective response rate, complete response rate, progression-free survival, and overall survival observed in a previous Phase II study.
-
Global Rights Retained
HUTCHMED retains all worldwide rights to HMPL-760, maximizing potential future revenue streams from the drug.
Analysis · HCM · Life Sciences
HUTCHMED's initiation of a registrational Phase III trial for HMPL-760 marks a significant advancement in its drug pipeline. This trial targets relapsed/refractory diffuse large B-cell lymphoma (DLBCL), a prevalent and aggressive cancer in China, representing a substantial market opportunity. The move to Phase III is supported by encouraging results from a prior Phase II study, suggesting HMPL-760, a third-generation BTK inhibitor, has promising efficacy and a manageable safety profile. Retaining global rights to the drug positions HUTCHMED to fully capitalize on its potential success, which could significantly impact the company's long-term growth trajectory and address a critical unmet medical need.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1268 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCM was trading at $13.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $11.51 to $19.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.